Peng W, Pu X, Jiang M, et al. - Because evidence of dacomitinib’s activity on brain metastasis is sparse, researchers analyzed a case series of 14 epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis managed with first-line dacomitinib. Follow-up of a median duration of 4.5 months was performed. The objective response rate and the disease control rate were estimated to be 92.9% (13/14) and 100%, respectively. In 12 of 14 patients (85.7%), experts found a measurable response of the intracranial metastases, including 12 of 13 (92.3%) with brain parenchymal metastasis; a lack of good response was evident in one patient with meningeal metastasis. Grade 1-2 adverse effects occurred in all patients, but none stopped treatment or needed a dosage adjustment. Overall, findings showed a potent effectiveness of dacomitinib for central nervous system metastasis in EGFR-positive NSCLC.